Human Chorionic Gonadotropin
DrugThe application of HCG(Human Chorionic Gonadotropin) in Luteal Support for frozen embryo transfer in Ovulation Cycle of Obese women: A single-center, open-label, randomized controlled trial study
Other names: HCG
NCT Number: NCT07633002
This study aims to explore whether the application of low-dose HCG in luteal support can improve the pregnancy outcomes of natural cycle frozen embryo transfer in obese patients
Trial opening soon.
Get Notified22 year–37 year
Female
Interventional
Not applicable
In ART, due to ovulation induction and the particularity of the population, luteal phase deficiency usually exists, and in clinical practice, luteal phase support is routinely strengthened. Progesterone is commonly used for luteal support in clinical practice. According to the Chinese expert consensus on luteal support, HCG can be used for luteal support in the absence of OHSS. HCG can increase progesterone secretion by endogenous stimulation of luteal function and exogenous addition of HCG to enhance luteal support, thereby increasing progesterone production and maintaining luteal function.
At present, it remains unclear whether HCG can improve pregnancy outcomes. Previous studies have indicated that compared with conventional luteal support, HCG has not significantly improved the pregnancy outcomes of frozen-thawed embryo transfer in ovulation cycles (NC). However, with the development and progress of FET technology, while reducing the impact of the technology on frozen embryos, we once again explored whether adding HCG on the basis of traditional luteal support in NC-FET could improve the pregnancy outcomes of obese or overweight patients, providing a theoretical basis for the clinical application of HCG.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The application of HCG(Human Chorionic Gonadotropin) in Luteal Support for frozen embryo transfer in Ovulation Cycle of Obese women: A single-center, open-label, randomized controlled trial study
Other names: HCG
Time frame: Pregnancy at 28 weeks or more
Infants with vital signs who were born after 28 weeks of gestation.
Time frame: Check HCG 14 days after embryo transfer
Pregnancy outcomes: biochemical pregnancy, clinical pregnancy, ongoing pregnancy, termination of pregnancy, ectopic pregnancy, miscarriage
The Second Hospital of Shandong University
Other
The Application of HCG in the Luteal Support of Frozen Embryo Transfer During Ovulation Cycles in Overweight and Obese Women
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05473767
Body Weight, Cardiovascular Diseases
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT06311799
Body Weight, Cardiovascular Diseases
Danville, Pennsylvania, United States
View Trial DetailsNCT06445530
Body Weight, Diabetes Mellitus
Baltimore, Maryland, United States
View Trial DetailsNCT05114174
Body Weight, Body Weight Changes
Santiago, Providencia, Chile
View Trial Details